Lmr Partners LLP Hutchmed (China) LTD Transaction History

Lmr Partners LLP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$16.25 - $20.23 $202,686 - $252,328	12,473 New	12,473 $225,000
Q4 2022 Feb 14, 2023	BUY	$7.65 - $15.51 $274,474 - $556,483	35,879 New	35,879 $530,000
Q3 2019 Nov 14, 2019	SELL	$17.84 - $22.69 $1.78 Million - $2.27 Million	-100,000 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$22.0 - $31.78 $2.2 Million - $3.18 Million	100,000 New	100,000 $2.29 Million

8.25M

3.8K

2.4K

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $3.11B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

Get notified when there are updates to the investment portfolio of Lmr Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Lmr Partners LLP with notifications on news.